Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.50 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.50 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.50 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.50 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | JAK3 | P52333 | 8/20 | 0.36 |
| ▸ | MET | P08581 | 4/20 | 0.36 |
| ▸ | RAF1 | P04049 | 2/20 | 0.35 |
| ▸ | KIT | P10721 | 1/20 | 0.34 |
| ▸ | KDR | P35968 | 1/20 | 0.34 |
| ▸ | FLT3 | P36888 | 1/20 | 0.34 |
| ▸ | AXL | P30530 | 2/20 | 0.34 |
| ▸ | MERTK | Q12866 | 2/20 | 0.34 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | MAPK3 | P27361 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31213915 | 0.94 | CYP3A4 (0.44) | CYP3A4CYP2D6FGFR1CYP2C9FGFR2 | |
| SCHEMBL31213843 | 0.93 | FGFR1 (0.54) | CYP3A4CYP2D6FGFR1CYP2C9FGFR2 | |
| SCHEMBL31214005 | 0.90 | FGFR1 (0.43) | CYP3A4CYP2D6FGFR1CYP2C9FGFR2 | |
| SCHEMBL31214014 | 0.90 | CYP3A4 (0.61) | CYP3A4CYP2D6FGFR1CYP2C9FGFR2 | |
| SCHEMBL31213930 | 0.89 | FGFR1 (0.43) | CYP3A4CYP2D6FGFR1CYP2C9FGFR2 | |
| SCHEMBL31213971 | 0.89 | CYP3A4 (0.43) | CYP3A4CYP2D6FGFR1CYP2C9FGFR2 | |
| SCHEMBL31213941 | 0.88 | CYP3A4 (0.45) | CYP3A4CYP2D6FGFR1CYP2C9FGFR2 | |
| SCHEMBL31213904 | 0.87 | FGFR1 (0.47) | CYP3A4CYP2D6FGFR1CYP2C9FGFR2 | |
| SCHEMBL31213934 | 0.87 | FGFR1 (0.47) | CYP3A4CYP2D6FGFR1CYP2C9FGFR2 | |
| SCHEMBL31213876 | 0.85 | FGFR1 (0.60) | CYP3A4CYP2D6FGFR1CYP2C9FGFR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240383905-A1 | FGFR INHIBITORS AND METHODS OF USE THEREOF | 3H PHARMACEUTICALS CO., LTD. (CN) | 2024-11-21 | — | — | US | claimed |
| US-20240383905-A1 | FGFR INHIBITORS AND METHODS OF USE THEREOF | 3H PHARMACEUTICALS CO., LTD. (CN) | 2024-11-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240383905-A1 | FGFR INHIBITORS AND METHODS OF USE THEREOF | FGFR1, FGFR3, FGFR4 | CYP3A4 594/4885CYP2D6 638/4885FGFR1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.